ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

REGN13089

A development code. Also written as “REGN13089-M404-M2980”.

Its studies are mostly in Carcinoma, Renal Cell, led by Regeneron Pharmaceuticals.

Furthest: phase 2, since Oct 2, 20261 company-led study, 1 open or runningNext primary completion: Mar 10, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals11 open or runningphase 2since Oct 2, 2026Oct 2, 2026Mar 10, 2031phase 2 · NCT07863024

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 2, 2026First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07863024 · 320 planned · United States

Ahead

  1. Mar 10, 2031Primary completion: phase 2 study in Carcinoma, Renal CellNCT07863024

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07863024Carcinoma, Renal Cell · United States2RecruitingMar 10, 2031320

How it is read

Names in the registry

  • “REGN13089-M404-M2980”, 1 entry

Codes read as this program: REGN13089.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.